Key result
Recombinant human thrombopoietin plus erythropoietin enhances CD34+ cell erythroid burst formation via the Mpl receptor.
Why the study?
The physiologic roles of recombinant human thrombopoietin (TPO) in human hematopoiesis and its potential clinical applications were not fully delineated.
Population
Human CD34+ bone marrow and cord blood cells in vitro
Comparison
TPO with erythropoietin vs TPO alone, interleukin-3, GM-CSF, steel factor, or soluble Mpl receptor
Design
In vitro experimental study
Authors
Loading...
Preclinical data only; does not support clinical use in anemia and leaves translational efficacy open.
Recombinant human thrombopoietin exhibits burst-promoting activity for erythroid progenitors in vitro when combined with erythropoietin, mediated via the Mpl receptor.
Kobayashi et al. (1995) studied Human hematopoiesis. Recombinant human thrombopoietin (TPO) vs. TPO alone, interleukin-3, granulocyte/macrophage colony-stimulating factor, steel factor was evaluated on Erythroid burst formation. Recombinant human thrombopoietin enhanced erythroid burst formation from CD34+ bone marrow and cord blood cells in the presence of erythropoietin, mediated through the Mpl receptor.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: